(Q51944474)

18 April 2018

title

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. (English)

1 reference

18 April 2018

mild cognitive impairment

0 references

1 reference

1 reference

2

Teipel SJ

1 reference

18 April 2018

12

Blennow K

1 reference

18 April 2018

Hampel H

1

1 reference

18 April 2018

Fuchsberger T

3

1 reference

18 April 2018

Andreasen N

4

1 reference

18 April 2018

Wiltfang J

5

1 reference

18 April 2018

Otto M

6

1 reference

18 April 2018

Shen Y

7

1 reference

18 April 2018

Dodel R

8

1 reference

18 April 2018

Du Y

9

1 reference

18 April 2018

Möller HJ

11

1 reference

18 April 2018

Buerger K

13

1 reference

18 April 2018

Farlow M

10

1 reference

18 April 2018

language of work or name

English

0 references

publication date

1 July 2004

1 reference

18 April 2018

published in

Molecular Psychiatry

1 reference

18 April 2018

volume

9

1 reference

18 April 2018

issue

7

1 reference

18 April 2018

page(s)

705-710

1 reference

18 April 2018

Mild cognitive impairment: clinical characterization and outcome

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Cerebrospinal protein tau is elevated in early Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

The Clinical Dementia Rating (CDR): current version and scoring rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

A longitudinal study of cognitive function in elderly persons with subjective memory complaints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Clinical characteristics of individuals with subjective memory loss in Western Australia: results from a cross-sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

7 January 2021

Increased cerebrospinal fluid tau in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

7 January 2021

Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

7 January 2021

CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001473

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001473

1 reference

18 April 2018

1 reference

18 April 2018